By Joshua Kirby
According to a Swiss pharmaceutical company, Novartis AG has reached an agreement to provide the cholesterol-lowering drug Lekbio to patients through the United Kingdom’s National Health Service.
According to Novartis, about 300,000 patients should be treated with Leqvio in three years. Patients of interest are those at high risk of having a second cardiovascular event.
This treatment is part of a population health care approach and aims to reduce long-term elevated LDL cholesterol in patients, a major modifiable risk factor for cardiovascular disease.
The collaboration with the NHS follows Leqvio’s final recommendation from the UK drug regulator NICE.
Write a letter to Joshua Kirby at firstname.lastname@example.org. @joshualeokirby
Novartis Offers Leqvio, a Cholesterol Fighter in the UK
Source link Novartis Offers Leqvio, a Cholesterol Fighter in the UK